UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Holdings in Altimmune, Inc. (NASDAQ:ALT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in Altimmune, Inc. (NASDAQ:ALT) by 24.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 79,266 shares of the company’s stock after selling 25,916 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.11% of Altimmune worth $487,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in ALT. Larson Financial Group LLC acquired a new position in shares of Altimmune in the third quarter valued at approximately $31,000. PFG Investments LLC acquired a new stake in Altimmune in the second quarter valued at $67,000. Principal Financial Group Inc. purchased a new position in Altimmune during the 2nd quarter valued at about $70,000. Verus Capital Partners LLC acquired a new position in shares of Altimmune during the 2nd quarter worth approximately $82,000. Finally, XTX Topco Ltd purchased a new stake in shares of Altimmune in the second quarter valued at $96,000. 78.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Altimmune in a report on Thursday, November 14th. UBS Group initiated coverage on Altimmune in a report on Tuesday, November 12th. They issued a “buy” rating and a $26.00 price target for the company. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Altimmune Price Performance

Shares of ALT stock opened at $8.25 on Friday. The firm has a market cap of $586.78 million, a price-to-earnings ratio of -5.32 and a beta of 0.15. The stock’s fifty day simple moving average is $7.93 and its 200 day simple moving average is $7.10. Altimmune, Inc. has a one year low of $5.28 and a one year high of $14.84.

Altimmune (NASDAQ:ALT) last released its earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million for the quarter. During the same period in the previous year, the company posted ($0.39) EPS. On average, research analysts anticipate that Altimmune, Inc. will post -1.36 earnings per share for the current year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.